Soligenix Inc. (NASDAQ: SNGX) announced that the European Commission has granted orphan drug designation to dusquetide (SGX945) for the treatment of Behçet Disease. The decision follows a positive recommendation from the European Medicines Agency and is supported by Phase 2a data demonstrating biological efficacy and safety. This designation provides up to 10 years of market exclusivity in the European Union upon marketing authorization, adding to existing FDA orphan drug and fast track designations for the same indication.
Behçet disease is a rare, chronic autoimmune condition characterized by inflammation of blood vessels, leading to oral and genital ulcers, skin lesions, and potentially severe organ involvement. Current treatment options are limited and often associated with significant side effects. Dusquetide, a first-in-class innate defense regulator (IDR), modulates the body's immune response to reduce inflammation without immunosuppression. The favorable safety profile and biological activity observed in the Phase 2a trial suggest dusquetide could address a significant unmet medical need.
Soligenix is advancing its IDR platform, with dusquetide also being evaluated for oral mucositis in head and neck cancer patients. The company recently completed a Phase 3 trial for HyBryte (synthetic hypericin sodium) in cutaneous T-cell lymphoma and is seeking regulatory approvals worldwide. The orphan drug designation in Europe, along with existing U.S. designations, provides incentives for development, including protocol assistance and reduced fees. For more information, visit https://ibn.fm/847sO.
The company's pipeline includes other candidates such as RiVax for ricin toxin, filovirus vaccines, and CiVax for COVID-19, supported by government funding from NIAID, DTRA, and BARDA. Soligenix's ThermoVax heat stabilization technology is also being utilized in vaccine development. With the EU orphan designation, Soligenix strengthens its position in rare autoimmune diseases, potentially offering a new therapeutic option for Behçet patients. For ongoing updates, see the company's newsroom at https://ibn.fm/SNGX.
